Shire's Vyvanse flunks depression studies; Glaxo re-ups its U.K. commitment;

@FierceBiotech: Biotech VC Clarus reaches for $375M in its latest fund. Story | Follow @FierceBiotech

@JohnCFierce: Martoma guilty in the bapineuzumab insider trading case. Can't say I'm surprised. They had him cold. Story via NYT | Follow @JohnCFierce

@DamianFierce: Biotech IPOs: $500M in a single week should accelerate some R&D efforts. More | Follow @DamianFierce

@EmilyMFierce: Stem cell lines not fit for clinic. Story via The Scientist | Follow @EmilyMFierce

> Shire's ($SHPG) ADHD blockbuster Vyvanse failed to improve the symptoms of depression in two Phase III studies, the company said, scuttling hopes for the drug in that indication. Article

> GlaxoSmithKline ($GSK) is planning to invest nearly $165 million in an aging U.K. facility, preserving at least 200 jobs once in peril. News

> The Department of Justice has declined to join in on a whistleblower lawsuit against Celgene ($CELG). Story

Medical Device News

@FierceMedDev: Myriad Genetics' performance and M&A plans produce investor bliss. Story | Follow @FierceMedDev

@MarkHFierce: Scottish startup Edinburgh Molecular Imaging pulled in more than $6.5 million in Series A financing. Release | Follow @MarkHFierce

@MichaelGFierce: Hot on FierceDrugDelivery: Pfizer snags electroporation device license from Ichor for cancer vaccine delivery. News | Follow @MichaelGFierce

@EmilyWFierce: Insulet packing up camp, making room for expansion. Article | Follow @EmilyWFierce

> LabCorp eked out year-end growth while Dx reimbursement problems remained. Report

> Sorin touts a big Q4 earnings boost in preliminary results. More

> FDA: Guidance for medical device interoperability standards is on its way. Item

Pharma News

@FiercePharma: AbbVie is hit with 5 lawsuits citing the dangers of its 'low T' drug. News | Follow @FiercePharma

@TracyStaton: Perhaps not coincidentally, best-read special report: Top 10 pharma layoffs of 2013. Report | Follow @TracyStaton

@EricPFierce: It is litigation seminar for pharma today. Roche halting Mylan's biosimilar launch, AbbVie sued over AndroGel & more. | Follow @EricPFierce

> Pradaxa files show drug marketers weighing in on how to communicate the drug's risks. Story

> Roche legal action puts a stop to Mylan's India launch of its Herceptin biosimilar. More

> Merck is ready to settle NuvaRing lawsuits for $100M. Piece

Suggested Articles

The FDA sent Eton's partner, Bausch Health, a complete response letter that raised “no concerns” about the clinical data in the drug’s application.

A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.

Boehringer signed a deal to buy out a small immuno-oncology player this morning, and AbbVie’s been at it, too, inking a deal to snap up Mavupharma.